Loading transcript...
Click for full transcript
Chapters & Sections (202)
▼
0:31
Banning Peptides for Profit and Public Health Concerns
1:03
Private Industry Influence on Government Decisions
1:34
Large Language Models and Data Quality Concerns
2:07
Historical Examples of Pharmaceutical Industry Misconduct
3:40
Eisenhower's Warning on Medical Industrial Complex
4:12
Big Pharma's History of Profiting Over Patient Outcomes
4:43
Hemophilia Drug Contamination and HIV Infection
5:15
Big Pharma's Actions in the 80s
5:46
Compounding Pharmacies and HIV Treatment Options
7:18
Patented Peptides and FDA Regulation
8:19
Insidious Influence of Big Pharma and Insurance Companies
8:50
Compliance and Indictment by Pharmacy Benefit Managers
10:55
Insurance Companies' Wait-and-See Approach and Bad Information
11:27
Government Influence and Lack of Checks and Balances
11:58
Compliance and the Department of Justice's Role
12:30
Doctors' Fears and Liberty Concerns
13:02
Federal Indictments and the Court of Public Opinion
14:05
Insurance Company Tactics and Asset Seizure
14:36
Concerns about FDA Seizures and DOJ Actions
15:08
Ibutamoren and Patenting of Peptides
15:40
FDA Decision-Making and Big Pharma Influence
16:13
Playing Devil's Advocate on Peptide Safety
16:45
FDA Classification and Litigation Risks
17:47
Compounding Pharmacy Capabilities and FDA Compliance
18:18
Independent Verification of Ingredients and Compounding Process
19:50
Compounding Pharmacies' Ability to Compound Safe and Effective Products
20:53
Regulation of Compounding Pharmacies by the FDA and Big Pharma
21:56
FDA's Inadequate Regulation and Impact on Minority Communities
22:28
Big Pharma's Tactics Against Compounding Pharmacies
23:02
FDA Inspection and Regulation of Pharmaceutical Facilities
23:33
Eli Lily's Facility Shut Down and FDA Inspection Failures
24:05
Manipulation of Media and Government by Pharmaceutical Companies
24:36
Challenges in Educating the Public about Pharmaceutical Industry Issues
25:07
Impact of Media Bias and Advertising on Public Trust
25:40
FDA Vaccine Approval and Industry Ties
26:11
Corruption at the FDA and DOJ
26:43
Insurance Company Influence on Healthcare
28:46
Physician Investment and Conflict of Interest
29:17
Pharmacy Investment and Kickbacks Explained
30:18
Investment Opportunities in Healthcare
31:21
BPC157 and its Effects on the Body
32:55
Opioid Pandemic and Black Market Risks
33:25
Purdue Pharma's Role in Opioid Epidemic
33:56
Risks of Nonhuman Use Sources for Peptides
34:28
Big Pharma's Misrepresentation and Outsourcing Practices
35:31
FDA Scrutiny and Big Pharma's Lack of Transparency
36:01
Burning Records and Falsified Data
36:32
Patent and FDA Choice
37:03
Adverse Events and Pharmacy Experience
38:05
Peptide Supplementation and FDA Regulation
39:07
Lack of Human Safety Trials in Medical Devices and Products
39:39
The 510k Approval Process Loophole
40:11
Daisy Chain of Untested Products in the Operating Room
40:43
Adverse Events and Underreporting
41:13
Tissue Buildup in Medical Equipment
42:47
Introduction to Extremophiles and their Resilience
43:19
Comparison of Adverse Events in Stem Cells and Biologics Products
43:49
Storage and Handling of Medical Equipment and Implants
45:22
Sharing of Surgical Instruments between Human and Animal Patients
46:24
Stem Cell Storage and Handling Protocols
46:55
Corruption in Traditional Medicine and Stem Cells
47:27
Personal Experience with Pharmaceutical Industry and Opioid Epidemic
49:00
Compounding Pharmacy and Non-Addictive Treatment Modalities
50:02
Retrospective Study Reveals Flawed Original Research
50:33
Understanding Prostate Cancer Risk and Testosterone Levels
51:03
Optimal Testosterone Ranges for Prostate Cancer Prevention
52:03
Challenging Healthcare Dogma and the Role of Pharmacy Benefit Managers
53:40
Rebates, Insurance Companies, and Misconceptions
55:14
Pharmacy Benefit Manager Fraud and Abuse
55:46
Insurance Model Critique and Cash Pay Alternative
56:16
Root Cause Analysis and Comprehensive Approach
57:17
Biomarker Test and Insurance Model Concerns
57:48
EEG Testing for Root Cause Analysis
58:19
Methylfolate Detoxification Test and Pharmacogenetic Testing
58:52
Gut Biome Test and Cytochrome P4 50 Variants
59:52
Critique of Conventional Medicine and Alternative Testing Options
1:00:23
Clinician Education and Carrots
1:00:55
Misconceptions in Cellular Therapies and Infrared Therapy
1:01:25
Infrared Therapy and its Benefits
1:02:26
NAD and Nmn Treatments for Healthcare
1:03:59
Challenges in Bringing Personalized Medicine to the Masses
1:04:30
Potential of Large Language Models in Medicine
1:05:02
Future of Medicine and AI-Powered Patient Experience
1:06:05
Artificial Intelligence and Large Language Models in Medicine
1:07:06
AI's Ability to Improve on Its Own
1:08:08
AI as a Tool for Good or Bad
1:09:10
Using AI to Scale Predictive Medicine
1:10:13
Scaling Health Care and Doctor Hourly Fees
1:10:44
Large Language Models in Healthcare
1:11:47
Real-Time Annotation and AI Integration
1:12:48
Future of Large Language Models in Healthcare
1:13:50
Avoiding Political or Ideological Influence in Large Language Models
1:14:20
Closed Infrastructure and Peer-Reviewed Data for Large Language Models
1:14:51
Building a Team of Experts to Develop and Improve Large Language Models
1:15:21
Using Large Language Models for Analytics and Decision-Making in Healthcare
1:15:51
Concerns about the FDA and Insurance Companies
1:17:25
Leaving a Greedy Ecosystem
1:17:56
Personal Experience with Treatments
1:18:28
Insurance and Managed Care
1:20:34
Red Light Therapy's Effectiveness in Osteoarthritis Treatment
1:21:07
Benefits of Red Light Therapy Beyond Osteoarthritis Treatment
1:21:38
Maintaining Physique and Energy Levels with Red Light Therapy
1:22:09
Low Testosterone and Red Light Therapy
1:23:42
Hormone Regulation and Fertility in Relation to Environment
1:24:12
Estrogen and Sex Hormones
1:24:42
Predictive, Proactive, Personalized Healthcare and Data Privacy
1:25:47
Insurance Companies and Large Language Models
1:26:18
Pharmacy Benefit Managers and the Insurance Model
1:26:49
Pharmacy Benefit Managers' Role in Negotiating Drug Prices
1:27:21
Fraud and Confusion in Insurance Companies' Practices
1:27:51
Tier Pricing and Profit Maximization by Pharmacy Benefit Managers
1:28:22
Insulin Pricing and Rebates
1:30:26
Pharmacy Acquisition and Insurance Company Behavior
1:31:29
Insurance Company Tactics and Pharmacy Benefit Managers
1:32:32
Profit-Driven System vs Patient Outcome
1:33:37
Monetizing Disease States and Preventing Cures
1:34:10
Government's Focus on Healthcare and Unnecessary Surgeries
1:34:41
Hospital System's Prioritization of Profits over Patient Outcomes
1:35:12
Primary Care and Pharmacy Issues with Insurance Companies
1:35:44
Impact of Epigenetics and Lifestyle Choices on Disease States
1:36:47
Oncologist Incentives and Patient Outcomes
1:37:51
Oncologist Income and Patient Choice
1:38:22
Virtual Care and Large Language Models
1:39:22
Establishing a Baseline for Health
1:39:54
Preventing Chronic Disease and Unlocking Stem Cells
1:41:27
Accessing Genetic Traits and Optimism
1:41:57
Measuring Progress and Proactivity
1:42:29
Artificial Intelligence in Brain Analysis
1:43:00
Precision Brain Rewiring and Treatment
1:44:34
Brain Mapping and Signal Optimization
1:45:04
Frequency of Brain and Potential Improvement
1:45:35
Applying Technology to High-Level Operators
1:46:07
Rare Brain Type and Potential
1:47:08
Assessing Brain Health and Neurowave
1:48:43
Partnership with Dell Medical University and Research Institute
1:49:13
Bruce Damer's Vision and Research on Psychedelics
1:49:43
Measuring the Effect of Psychedelics on Brain Performance
1:51:17
Stem Cells and Misconceptions
1:52:18
Heterochronic Parabiosis and its Occurrence in Pregnancy
1:53:21
HSCs and Cellular Treatment Options
1:54:22
Limitations of Current Cellular Treatment Options and the Importance of Minimal Dosage
1:55:55
Limitations of Birth-Derived Tissue and Importance of Differentiation
1:56:26
Mechanism of Action in Cellular Treatment Modalities
1:56:59
RNA and Extracellular Vesicles in Cellular Treatment
1:57:30
Challenges and Misconceptions in Orthopedic Treatment
1:59:36
Aaron Rogers' Injury and Treatment Approach
2:00:06
NFL Athletes' Results with Heterochronic Parabiosis
2:00:36
Misunderstandings and Dogma in the Medical Field
2:01:07
Cellular and Acellular Treatment Options
2:02:42
Future of Stem Cell Research and Trials
2:03:14
Potential for Cartilage Rebuilding with Umbilical Cord Cells
2:04:16
Current Knee Replacement Surgery and Weight Loss
2:05:53
Combination Therapy for Osteoarthritis Treatment
2:06:23
Statistical Improvement in Cartilage Loss and MRI Scans
2:06:57
Mechanism of Action in Regenerative Medicine
2:07:29
Cellular Treatments and Skin Health
2:08:01
Combining Cellular Treatments with Other Modalities
2:08:32
Resistance to Regenerative Medicine and Aaron Rogers' Injury
2:09:34
Aaron's Unique Approach to Recovery and Healing
2:10:04
Discussion of Red Light Therapy, Hyperbaric Treatment, and Other Alternative Methods
2:11:40
The Importance of Optimizing the Healing Process and Exploring Alternative Treatment Options
2h 58m⏭ 2
2h 21m⏭ 3
2h 53m⏭ 2
3h 1m⏭ 2
2h 54m⏭ 2
3h 35m
3h 7m⏭ 2
2h 39m⏭ 2
2h 58m⏭ 2
2h 34m⏭ 3
2h 19m
2h 49m⏭ 2
1h 42m⏭ 3
1h 18m⏭ 4
1h 6m⏭ 1
1h 6m⏭ 3
38m
2h 37m⏭ 2
2h 0m⏭ 2
1h 14m⏭ 2
1h 9m⏭ 3
1h 17m
1h 1m
1h 14m⏭ 1